MX2021000043A - Activadores de la respuesta a proteinas desplegadas. - Google Patents

Activadores de la respuesta a proteinas desplegadas.

Info

Publication number
MX2021000043A
MX2021000043A MX2021000043A MX2021000043A MX2021000043A MX 2021000043 A MX2021000043 A MX 2021000043A MX 2021000043 A MX2021000043 A MX 2021000043A MX 2021000043 A MX2021000043 A MX 2021000043A MX 2021000043 A MX2021000043 A MX 2021000043A
Authority
MX
Mexico
Prior art keywords
cancer cells
erî
activators
small molecules
resistant
Prior art date
Application number
MX2021000043A
Other languages
English (en)
Inventor
Paul J Hergenrother
David J Shapiro
Matthew W Boudreau
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2021000043A publication Critical patent/MX2021000043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Conjunto de biomoduladores ERa de moléculas pequeñas que destruyen las células cancerosas de mama, ovario y endometrio ERa positivas resistentes a la terapia. Estas pequeñas moléculas tienen un mayor potencial terapéutico debido a la mayor capacidad para destruir las células de cáncer de mama resistentes a la terapia en comparación con BHPI y otras terapias convencionales (terapias endocrinas, tamoxifeno y fulvestrant/ICI). Los nuevos compuestos no solo inhiben la proliferación de las células cancerosas, sino que también realmente las destruye, lo que evita la reactivación de los tumores años después.
MX2021000043A 2018-07-03 2019-07-01 Activadores de la respuesta a proteinas desplegadas. MX2021000043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693641P 2018-07-03 2018-07-03
PCT/US2019/040058 WO2020009958A1 (en) 2018-07-03 2019-07-01 Activators of the unfolded protein response

Publications (1)

Publication Number Publication Date
MX2021000043A true MX2021000043A (es) 2021-03-25

Family

ID=69059783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000043A MX2021000043A (es) 2018-07-03 2019-07-01 Activadores de la respuesta a proteinas desplegadas.

Country Status (22)

Country Link
US (3) US20210276951A1 (es)
EP (1) EP3817741A4 (es)
JP (1) JP2021529757A (es)
KR (1) KR20210027382A (es)
CN (1) CN112423743A (es)
AU (1) AU2019299221A1 (es)
BR (1) BR112020025591A2 (es)
CA (1) CA3103958A1 (es)
CL (1) CL2020003423A1 (es)
CO (1) CO2020016690A2 (es)
CR (1) CR20210060A (es)
DO (1) DOP2020000256A (es)
EA (1) EA202190146A1 (es)
EC (1) ECSP20084330A (es)
IL (1) IL279429A (es)
JO (1) JOP20200344A1 (es)
MA (1) MA53105A (es)
MX (1) MX2021000043A (es)
PE (1) PE20210662A1 (es)
PH (1) PH12020552223A1 (es)
SG (1) SG11202012902WA (es)
WO (1) WO2020009958A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103958A1 (en) 2018-07-03 2020-01-09 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response
WO2021222738A1 (en) * 2020-05-01 2021-11-04 The Board Of Trustees Of The University Of Illinois Compounds for estrogen receptor positive cancers
WO2022020605A1 (en) * 2020-07-23 2022-01-27 The Board Of Trustees Of The University Of Illinois Treatment of metastasized estrogen receptor positive breast cancer
WO2022032146A1 (en) * 2020-08-07 2022-02-10 Systems Oncology, Llc Methods for inhibiting growth of era positive cancers
MX2023004480A (es) * 2020-10-23 2023-05-04 Univ Illinois Compuestos anticancerigenos selectivos para canceres er-positivos.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250442B2 (en) 2002-03-15 2007-07-31 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
EP1718611A4 (en) * 2004-02-13 2009-09-23 Harvard College 3-3-DI-SUBSTITUTED OXINDOLES AS INHIBITORS OF INITIATION OF TRANSLATION
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US20070299102A1 (en) * 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer
AR056544A1 (es) 2005-09-29 2007-10-10 Wyeth Corp Derivados fenilaminopropanol y metodos de uso de los mismos
PA8743601A1 (es) 2006-08-24 2009-02-09 Wyeth Corp Proceso para preparar derivados de indonelinona fenilaminopropanol
WO2008071387A1 (en) * 2006-12-11 2008-06-19 Topotarget A/S Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers
JP2010525024A (ja) 2007-04-24 2010-07-22 トポターゲット・アクティーゼルスカブ 置換３−（４−ヒドロキシフェニル）−インドリン−２−オン化合物
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
WO2010109008A1 (en) 2009-03-26 2010-09-30 Topotarget A/S Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
US20160106711A1 (en) 2012-09-20 2016-04-21 President And Fellows Of Harvard College 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation
US9316631B1 (en) 2012-10-19 2016-04-19 Whitehead Institute For Biomedical Research ER-stress inducing compounds and methods of use thereof
CA2898732A1 (en) * 2013-01-18 2014-07-24 Mao CHENGJIAN Estrogen receptor inhibitors
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
PT3004090T (pt) 2013-05-28 2017-12-22 Astrazeneca Ab Compostos químicos
CA3103958A1 (en) 2018-07-03 2020-01-09 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response

Also Published As

Publication number Publication date
WO2020009958A1 (en) 2020-01-09
EA202190146A1 (ru) 2021-04-27
CN112423743A (zh) 2021-02-26
US20200190029A1 (en) 2020-06-18
US20210340100A1 (en) 2021-11-04
US11584718B2 (en) 2023-02-21
US20210276951A1 (en) 2021-09-09
PH12020552223A1 (en) 2021-06-28
SG11202012902WA (en) 2021-01-28
US11046647B2 (en) 2021-06-29
DOP2020000256A (es) 2021-03-15
IL279429A (en) 2021-01-31
JOP20200344A1 (ar) 2020-12-31
CL2020003423A1 (es) 2021-05-14
BR112020025591A2 (pt) 2021-03-23
CR20210060A (es) 2021-04-08
EP3817741A1 (en) 2021-05-12
CA3103958A1 (en) 2020-01-09
JP2021529757A (ja) 2021-11-04
EP3817741A4 (en) 2022-07-06
CO2020016690A2 (es) 2021-01-18
MA53105A (fr) 2021-05-12
KR20210027382A (ko) 2021-03-10
ECSP20084330A (es) 2021-01-29
AU2019299221A1 (en) 2021-02-04
PE20210662A1 (es) 2021-03-31

Similar Documents

Publication Publication Date Title
MX2021000043A (es) Activadores de la respuesta a proteinas desplegadas.
MX2020011746A (es) Terapias genicas para los trastornos lisosomales.
PH12018502429A1 (en) Antibody molecules for cancer treatment
CL2018002683A1 (es) Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
MX2020011745A (es) Terapias genicas para los trastornos lisosomales.
MX2020011748A (es) Terapias genicas para los trastornos lisosomales.
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
MX2018011035A (es) Anticuerpos-anti-mica.
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2019010149A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
WO2018138032A3 (en) NKp46 BINDING AGENTS
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
MX2021005377A (es) Terapias dirigidas a cdcp1.
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
EA201990370A1 (ru) Терапия рака, связанная с crebbp
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES